CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer

Area of Science:

• Cancer Biology
• Immunology
• Molecular Biology

Background:

• Alternative cleavage and polyadenylation (APA) impacts cancer biology, but its role in anti-tumor immunity is understudied.
• Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poorly understood immune microenvironment.

Purpose of the Study:

• To investigate the role of APA-related gene CSTF2 in anti-tumor immunity within PDAC.
• To identify therapeutic strategies targeting CSTF2 to enhance anti-tumor immune responses.

Main Methods:

• Identification of CSTF2 as a key regulator of anti-tumor immunity in PDAC.
• Analysis of CSTF2's mechanism involving CXCL10 expression and innate T cell function.
• Evaluation of Forsythoside B as a CSTF2 inhibitor in preclinical models.

Main Results:

• CSTF2 was identified as a suppressor of anti-tumor immunity, inhibiting innate T cell (iαβT) infiltration and function in PDAC.
• CSTF2 reduces CXCL10 expression by affecting PolyA polymerase alpha (PAPα) binding, leading to decreased RNA stability.
• Forsythoside B, a CSTF2 inhibitor, demonstrated potential in activating anti-tumor immunity and overcoming resistance to immune checkpoint blockade (ICB).

Conclusions:

• CSTF2 plays a critical role in suppressing anti-tumor immunity in PDAC.
• Targeting CSTF2 with agents like Forsythoside B represents a promising therapeutic strategy for PDAC.
• This approach could enhance patient response to ICB therapy and overcome treatment resistance.